{"id":537,"date":"2026-02-27T08:29:17","date_gmt":"2026-02-27T08:29:17","guid":{"rendered":"http:\/\/mahmutcanyagmurdur.com.tr\/?p=537"},"modified":"2026-02-27T09:14:04","modified_gmt":"2026-02-27T09:14:04","slug":"1-malign-meme-hastaliklarinda-tedavi-yaklasimi","status":"publish","type":"post","link":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/surgery\/1-malign-meme-hastaliklarinda-tedavi-yaklasimi\/","title":{"rendered":"1.MAL\u0130GN MEME HASTALIKLARINDA TEDAV\u0130 YAKLA\u015eIMI"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"537\" class=\"elementor elementor-537\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aaa1866 e-flex e-con-boxed e-con e-parent\" data-id=\"aaa1866\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-73ef291 elementor-widget elementor-widget-heading\" data-id=\"73ef291\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p class=\"MsoNormal\"><b><span style=\"font-size:14.0pt;line-height:115%\">1.A.Meme kanseri insidans\u0131 <\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6cc92ba elementor-widget elementor-widget-text-editor\" data-id=\"6cc92ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Meme kanseri insidans\u0131, 1940 y\u0131l\u0131ndan bu yana A.B.D de yap\u0131lan istatistiksel verilere g\u00f6re her y\u0131l i\u00e7in %1 olarak verilmektedir.(1) Maalesef, son 50 y\u0131l i\u00e7inde tan\u0131 ve tedavi y\u00f6ntemlerindeki ilerlemelere ra\u011fmen meme kanserine ba\u011fl\u0131 mortalite oran\u0131nda de\u011fi\u015fme olmad\u0131\u011f\u0131 g\u00f6r\u00fclmektedir. &nbsp;Bilindi\u011fi \u00fczere meme kanseri daha \u00e7ok end\u00fcstrile\u015fmi\u015f \u00fclkelerin hastal\u0131\u011f\u0131 olarak bilinmektedir.<br><span style=\"font-style: inherit; text-transform: inherit;\"><br>Waterhouse ve ark. taraf\u0131ndan d\u00fcnya n\u00fcfusu \u00fczerinde ya\u015f standardizasyonu yap\u0131larak elde edilen verilere g\u00f6re en y\u00fcksek insidans end\u00fcstrile\u015fmi\u015f \u00fclkelerde g\u00f6r\u00fclmekle birlikte, en d\u00fc\u015f\u00fck insidans Asya ve Afrika pop\u00fclasyonlar\u0131nda g\u00f6r\u00fclmektedir. Orta Amerika ve Akdeniz \u00fclkeleri ise bu ikisinin aras\u0131nda yer almaktad\u0131r.(2)(\u015eekil 1) Bat\u0131 \u00fclkelerine son zamanlarda artan g\u00f6\u00e7lerle beraber \u00e7evresel oldu\u011fu d\u00fc\u015f\u00fcn\u00fclen etmenlerin ve de\u011fi\u015fen ya\u015fam tarz\u0131n\u0131n, geli\u015fmemi\u015f \u00fclkelerden geli\u015fmi\u015f \u00fclkelere g\u00f6\u00e7 eden n\u00fcfusta kanser insidans\u0131n\u0131 artt\u0131rmas\u0131 tabloyu daha belirgin hale getirmektedir.(3) \u00d6te yandan epidemiyolojik olarak 70 ya\u015f\u0131na kadar olan kad\u0131n pop\u00fclasyonun %10\u2019u meme kanserine yakalanmaktad\u0131r.(4) Ancak meme kanserinden \u00f6l\u00fcm oran\u0131n\u0131n geli\u015fmekte olan \u00fclkelerde daha y\u00fcksek oldu\u011fu da bilinmektedir.<br><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br>GLOBOCAN verilerine g\u00f6re d\u00fcnyada en \u00e7ok tan\u0131 konulan kanserler aras\u0131nda meme kanseri %11.9 ile ikinci s\u0131rada yer almaktad\u0131r. Son zamanlarda meme kanserinin insidans\u0131nda bir art\u0131\u015f dikkat \u00e7ekmektedir. Kad\u0131nlarda meme kanseri insidans\u0131n\u0131n \u00f6nceki d\u00f6nemlere g\u00f6re %20 oran\u0131nda ve meme kanserinden \u00f6l\u00fcmlerin ise %14 oran\u0131nda artt\u0131\u011f\u0131 ifade edilmektedir. T\u00fcrkiye Birle\u015fik Veri Taban\u0131 istatistiklerine g\u00f6re \u00fclkemizde 38.6\/100.000 ile meme kanseri kad\u0131n kanserlerinde ilk s\u0131rada yer almaktad\u0131r.(\u015eekil 2) \u00d6zmen ve ark. \u00e7al\u0131\u015fmalar\u0131na g\u00f6re, \u00fckemizde meme kanseri s\u0131kl\u0131\u011f\u0131 ve mortalitesi artmakta oldu\u011fu y\u00f6n\u00fcndeki TMHD veri taban\u0131na g\u00f6re yapt\u0131klar\u0131 \u00e7al\u0131\u015fma da bu bulgular\u0131 desteklemektedir. Ayn\u0131 \u00e7al\u0131\u015fmada toplum tabanl\u0131 tarama program\u0131 ve fark\u0131ndal\u0131\u011f\u0131n olmamas\u0131 erken evre meme kanseri oran\u0131n\u0131n d\u00fc\u015f\u00fck olmas\u0131na neden olmaktad\u0131r.(5)<br><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br>Erken tan\u0131n\u0131n sa\u011f kal\u0131m \u00fczerindeki etkisi tart\u0131\u015fmas\u0131zd\u0131r. \u201cHuman maintenance organisation\u201d (HMO) verilerine g\u00f6re meme ile ilgili yak\u0131nmalar nedeniyle hekime ba\u015fvurular son 10 y\u0131lda %16 oran\u0131na ula\u015fm\u0131\u015ft\u0131r.(6,7) G\u00fcn\u00fcm\u00fczde, meme biyopsileri t\u00fcm cerrahi patoloji \u00f6rnekleme y\u00f6ntemleri i\u00e7inde %5 oran\u0131nda bir yer kaplamaktad\u0131r. Her ne kadar ba\u015fvuran hastalardaki bir \u00e7ok klinik semptom \u00e7o\u011funlukla benign meme hastal\u0131klar\u0131 ile ili\u015fkili olsa da ayaktan ba\u015fvurular\u0131n %4 \u00fc kanser tan\u0131s\u0131 almaktad\u0131r.(7)<br><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br>Sa\u011flanan bir \u00e7ok geli\u015fmeye kar\u015f\u0131n, 50 ya\u015f\u0131n alt\u0131ndaki hastalarda kanserin erken tan\u0131s\u0131 zorlu\u011funu korumaktad\u0131r. Geli\u015fmemi\u015f \u00fclkelere meme kanserini tarama, te\u015fhis ve tedavi imkanlar\u0131na ula\u015fmas\u0131n\u0131n kolay\u015fat\u0131r\u0131lmas\u0131 bu kanser t\u00fcr\u00fcyle m\u00fccadeleyi olumlu etkileyecektir.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6102af9 elementor-widget elementor-widget-heading\" data-id=\"6102af9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p class=\"MsoNormal\"><b><span style=\"font-size:14.0pt;line-height:115%\">1.B. Meme kanseri etyolojisi<\/span><\/b><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1857cc8 elementor-widget elementor-widget-text-editor\" data-id=\"1857cc8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Meme kanseri etyolojisinde rol oynayan etkenler, co\u011frafik etkenler, radyasyon etkileri, elektromanyetik alanlarda ya\u015fama, \u00e7evresel kirlilik, reprod\u00fcktif etkenler, gen\u00e7 ya\u015flarda maruz kal\u0131nan ve ilerde meme kanserine neden olabilecek \u00e7evresel etkenler olarak incelenebilir.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4726193 elementor-widget elementor-widget-heading\" data-id=\"4726193\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">B.1.Co\u011frafik  etkenleri<\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3e59189 elementor-widget elementor-widget-text-editor\" data-id=\"3e59189\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>N\u00fcfus esas al\u0131narak yap\u0131lan A.B.D kaynakl\u0131 \u00e7al\u0131\u015fmalar, meme kanseri insidans\u0131 ve n\u00fcfus yo\u011funlu\u011fu aras\u0131nda do\u011frusal bir ili\u015fki oldu\u011funu g\u00f6stermi\u015ftir (20). \u00d6te yandan bu \u00e7al\u0131\u015fmalarda; d\u00fc\u015f\u00fck parite, y\u00fcksek gelir d\u00fczeyi, y\u00fcksek e\u011fitim d\u00fczeyi meme kanseri prevalans\u0131nda artmaya neden olarak b\u00f6lgesel anlamda farkl\u0131l\u0131klar olu\u015fturmaktad\u0131r (21). Son \u00e7al\u0131\u015fmalarda, g\u00fcne\u015f \u0131\u015f\u0131\u011f\u0131n\u0131 az alan \u00fclkelerde ya\u015fayan n\u00fcfusta meme kanseri insidans\u0131 y\u00fcksek bulunmaktad\u0131r (25,27). Yap\u0131lan in vitro \u00e7al\u0131\u015fmalarda Vit D\u2019nin meme kanseri \u00fczerinde inhibit\u00f6r rol oynad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. G\u00fcne\u015f \u0131\u015f\u0131\u011f\u0131n\u0131n ciltte Vit D sentezi i\u00e7in gerekli oldu\u011fu g\u00f6z \u00f6n\u00fcne al\u0131n\u0131rsa kuzey \u00fclkelerindeki meme kanseri insidans\u0131 y\u00fcksekli\u011fi belki a\u00e7\u0131klanabilir.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-24da97f elementor-widget elementor-widget-heading\" data-id=\"24da97f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">B.2.Radyasyon<\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a0d03c elementor-widget elementor-widget-text-editor\" data-id=\"2a0d03c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Radyasyonun meme kanseri geli\u015fimindeki rol\u00fc uzun s\u00fcre bilinmektedir. Do\u011fada UV \u0131\u015f\u0131nlar\u0131 ve toprakta depolanan Radon do\u011fal radyasyon kaynaklar\u0131d\u0131r. Ancak meme kanserinde iyatrojenik veya beklenmedik dozda radyasyon maruziyeti kanser nedeni olarak kabul edilmektedir. Burada \u00f6nemli bir konu iyatrojenik veya kazai radyasyona maruz kal\u0131nan ya\u015f\u0131n meme kanseri olu\u015fumunda \u00f6nemli oldu\u011fudur. T\u00fcberk\u00fcloz tedavisi, omurga anomalileri v.b gibi s\u00fcrekli takip ama\u00e7l\u0131 radyolojik g\u00f6r\u00fcnt\u00fcleme zorunlulu\u011fu belli ba\u015fl\u0131 nedenler aras\u0131nda say\u0131labilir. \u00d6te yandan, g\u00fcn\u00fcm\u00fczde, her ne kadar 40 ya\u015f sonras\u0131 kad\u0131nlarda mamografi s\u0131ras\u0131nda al\u0131nan radyasyonun kanser geli\u015fimi konusunda etken oldu\u011funu g\u00f6steren kan\u0131t olmasa da\u00a0 dikkatler mammografik incelemelerin sorgulanmas\u0131 gerekti\u011fi \u00fczerinde yo\u011funla\u015fmaktad\u0131r. Son zamanlarda, meme kanserinde \u201cerror triad\u201d tan\u0131mlanm\u0131\u015ft\u0131r. Bu triad\u0131n bile\u015fenleri<br \/><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>-40 l\u0131 ya\u015flarda \u00e7ekilen mamografilerin\u00a0 BIRADS 0 olarak yorumlanmas\u0131<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">-Hastan\u0131n bir yak\u0131nma ile hekime ba\u015fvurmas\u0131<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">-Hekimin muayene bulgusu olmamas\u0131<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>olarak tan\u0131mlanmaktad\u0131r. Bir \u00e7al\u0131\u015fmada mamografi s\u0131ras\u0131nda hastan\u0131n maruz kald\u0131\u011f\u0131 radyasyonun 18\/100.000 insidans ile meme kanserine neden olabilece\u011fi bildirilmi\u015ftir (x). Bu nedenle tarama mamografilerinin s\u0131kl\u0131\u011f\u0131 tart\u0131\u015fmaya a\u00e7\u0131lm\u0131\u015ft\u0131r. Ancak hen\u00fcz mevcut standart uygulamay\u0131 de\u011fi\u015ftirebilecek yeterli veri elimizde yoktur.\u00a0 \u00a0<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Parite de radyasyona maruz kal\u0131nan ya\u015fa ilaveten etyolojide d\u00fc\u015f\u00fcn\u00fclmesi gereken bir konudur. Repro\u00fcktif d\u00f6nemde iyatrojenik veya insidental radyasyona maruz nullipar bir kad\u0131n\u0131n, do\u011fum yapm\u0131\u015f olan reprod\u00fcktif \u00e7a\u011fdaki bir kad\u0131na g\u00f6re meme kanseri y\u00f6n\u00fcnden riski daha fazlad\u0131r. Mesleki olarak (hava yolu \u00e7al\u0131\u015fanlar\u0131, radyoloji teknisyenleri v.b) d\u00fc\u015f\u00fck doz \u00e7evresel radyasyona maruziyetin meme kanserinin geli\u015fimi ve mortalitesi \u00fczerine etkisinin olmad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir (32,41,42).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-020533e elementor-widget elementor-widget-heading\" data-id=\"020533e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">B.3.Elektromanyetik etkiler<\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a3cf9b0 elementor-widget elementor-widget-text-editor\" data-id=\"a3cf9b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>G\u00fcn\u00fcm\u00fczde, dola\u015fan kandaki melatonin hormonu salg\u0131lanmas\u0131n\u0131n, \u00f6strojen hormonu d\u00fczeyini azaltt\u0131\u011f\u0131 y\u00f6n\u00fcnde g\u00f6r\u00fc\u015fler yo\u011funluk kazanmaktad\u0131r. Bir \u00e7ok in vitro ve in vivo hayvan \u00e7al\u0131\u015fmalar\u0131 elektromanyetik alanlar (EMA), melatonin ve \u00f6strojen hormonu ili\u015fkisi ile meme kanseri olu\u015fumu do\u011frudan ili\u015fki oldu\u011funu g\u00f6steren \u00e7al\u0131\u015fmalar vard\u0131r (49,52). Y\u00fcksek gerilim hatlar\u0131, bunlar ile ba\u011flant\u0131l\u0131 olarak transformat\u00f6r noktalar\u0131 ve \u00e7e\u015fitli elektrikli ev aletleri ve elektronik ayg\u0131tlar\u0131n bir EMA varl\u0131\u011f\u0131 olu\u015fturduklar\u0131 bilinmektedir. Bu durumun meme kanseri olu\u015fumunu kolayla\u015ft\u0131rd\u0131\u011f\u0131 y\u00f6n\u00fcndeki \u00e7al\u0131\u015fmalar\u0131n daha da desteklenmesi ka\u00e7\u0131n\u0131lmazd\u0131r (59,60).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fa35a43 elementor-widget elementor-widget-heading\" data-id=\"fa35a43\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">B.4.Zehirli at\u0131klar<\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f86b99d elementor-widget elementor-widget-text-editor\" data-id=\"f86b99d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Zehirli at\u0131klar ve meme kanseri ili\u015fkisi \u00fczerine yap\u0131lan epidemiyolojik \u00e7al\u0131\u015fmalar \u00f6zellikle organoklorin bile\u015fikleri \u00fczerine yo\u011funla\u015fm\u0131\u015ft\u0131r. Bunlar\u0131n ba\u015f\u0131nda pestisidler (tricloromethane=DDT, chlordane, hexachlorobenzen) gelmektedir. \u00d6te yandan baz\u0131 end\u00fcstriyel kimyasallar\u0131n ve onlar\u0131n metabolitlerinin s\u00fct s\u0131v\u0131s\u0131na ge\u00e7ebilece\u011fi, hatta memenin duktal epitel h\u00fccrelerine do\u011frudan 17-\u03b2-estradiol benzeri etki yaparak meme kanserine neden olabilece\u011fine dair g\u00f6r\u00fc\u015fler vard\u0131r. Bu tip etkiyi yapan end\u00fcstriyel kimyasallar\u0131n ba\u015f\u0131nda polibromine bifeniller gelmektedir. Ancak dioxin (polychlorinated dibenzo furan) maddesi de bir end\u00fcstriyel kimyasal olmakla birlikte, hayvan deneylerinde meme kanserine neden olmakla birlikte, anti\u00f6strojen etkiye sahip olabilece\u011fi bilinmektedir. Bu nedenle bu konuda ileri \u00e7al\u0131\u015fmalara ihtiya\u00e7 vard\u0131r.<br \/><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Pestisidler, \u00f6zellikle organoklorin bile\u015fikleri lipofilik maddeler olup metabolize edilebilmeleri g\u00fc\u00e7 ve dolay\u0131s\u0131 ile organizmadan at\u0131lmalar\u0131 zordur (66).\u00a0 DDT v.b bu gibi maddelere et, s\u00fct ve bal\u0131k t\u00fcketimi ile maruz kal\u0131nabilece\u011finden, bu gibi maddelerin kullan\u0131m\u0131n\u0131n s\u0131n\u0131rland\u0131r\u0131lmas\u0131 gerekti\u011fi art\u0131k tart\u0131\u015fma g\u00f6t\u00fcrmemektedir (70).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-075a6a2 elementor-widget elementor-widget-heading\" data-id=\"075a6a2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">B.5.Reprod\u00fcktif etkenler <\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fb7d8b6 elementor-widget elementor-widget-text-editor\" data-id=\"fb7d8b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Bilindi\u011fi \u00fczere ayn\u0131 \u00e7evresel \u015fartlar\u0131 payla\u015fan kad\u0131nlarda, erken menar\u015f, ge\u00e7 menopoz, hi\u00e7 do\u011fum yapmam\u0131\u015f olmak, ilk do\u011fum ya\u015f\u0131n\u0131n ileri ya\u015flarda olmas\u0131 meme kanseri riskini art\u0131rmaktad\u0131r. Bu durum do\u011frudan over fonksiyonlar\u0131 ile ilgilidir. Cerrahi ve kimyasal ooferektominin meme kanseri riskini azaltt\u0131\u011f\u0131 uzun s\u00fcredir bilinmektedir.<br \/><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Over fonksiyonlar\u0131ndaki azalman\u0131n, melatonin d\u00fczeyindeki artmayla olan ili\u015fkili oldu\u011fu ve bunun sonucunda meme kanseri riskinin azalmas\u0131n\u0131n s\u00f6z konusu oldu\u011funu g\u00f6steren klinik \u00e7al\u0131\u015fmalar bulunmaktad\u0131r (81-4). Bu \u00e7al\u0131\u015fmalar\u0131n sonu\u00e7lar\u0131na g\u00f6re endokrin dengeye etki ederek meme kanseri geli\u015fimine etki eden en \u00f6nemli \u00e7evresel fakt\u00f6r\u00fcn \u0131\u015f\u0131k oldu\u011fu sonucuna var\u0131labilir. Over fonksiyonlar\u0131n\u0131n ba\u015flad\u0131\u011f\u0131n\u0131n \u00f6nemli g\u00f6stergesi menar\u015ft\u0131r. Geli\u015fmi\u015f \u00fclkelere erken menar\u015f s\u0131kl\u0131\u011f\u0131 artmaktad\u0131r.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Hipotalamustaki suprakiasmatik nukleusun n\u00f6rohumoral etki ile pit\u00fciter ve gonadal endokrin fonksiyonlara etkisi melatonin dengesiyle yak\u0131ndan ilgilidir. Melatonin salg\u0131s\u0131ndaki \u0131\u015f\u0131k ve karanl\u0131k etkisinin gonadal fonksiyonlar\u0131n ba\u015flamas\u0131ndaki rol\u00fc halen ayd\u0131nlat\u0131lmay\u0131 beklemektedir.\u00a0 \u00a0\u00a0<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Gebelik ve hCG etkisinin meme kanserinden koruyucu etkisi ya\u015fa ba\u011fl\u0131 olarak d\u00fc\u015f\u00fcn\u00fclebilir. Epidemiyolojik bir \u00e7al\u0131\u015fma ilk do\u011fum ya\u015f\u0131n\u0131n 30-35 sonras\u0131 ve 20 ya\u015f\u0131n alt\u0131nda olmas\u0131n\u0131 da meme kanseri geli\u015fimi i\u00e7in risk olarak kabul edilebilece\u011fi y\u00f6n\u00fcnde sonu\u00e7 vermektedir (75-9).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-416d854 elementor-widget elementor-widget-heading\" data-id=\"416d854\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">B.6.Reprod\u00fcktif d\u00f6nemde maruz kal\u0131nan \u00e7evresel etmenler <\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a3b21ac elementor-widget elementor-widget-text-editor\" data-id=\"a3b21ac\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>\u00d6nemli bir toplumsal sorun olan sigara kullan\u0131m\u0131, kad\u0131nlar aras\u0131nda yayg\u0131nla\u015fmaktad\u0131r. Sigaraya ba\u015flama ya\u015f\u0131n\u0131n daha erken ya\u015flara kayd\u0131\u011f\u0131 da g\u00f6z \u00f6n\u00fcne al\u0131n\u0131rsa konunun \u00f6nemi daha da belirginle\u015fir. \u00dclkemizde\u00a0 her y\u0131l neredeyse 100 bin den fazla ki\u015fi sigaraya ba\u011fl\u0131 hastal\u0131klar nedeniyle \u00f6lmektedir. T\u00fcrkiyede yakla\u015f\u0131k 20 milyon ki\u015finin sigara kulland\u0131\u011f\u0131 tahmin edilmektedir. Geli\u015fmi\u015f \u00fclkelerde bu tablo daha da dramatik olup \u00f6rne\u011fin ABD de kad\u0131nlar\u0131n %22 si\u00a0 sigara kullanmaktad\u0131r. Bu nedenle kad\u0131nlarda en s\u0131k \u00f6l\u00fcm nedeni olarak akci\u011fer kanseri meme kanserini yakalam\u0131\u015f bulunmaktad\u0131r. Sigaran\u0131n i\u00e7erdi\u011fi benz-piren ve polisiklik hidrokarbonlar metabolize edilerek meme dokusunda karsinojenik epitelyal de\u011fi\u015fikliklere neden olabilmektedir. Son zamanlarda yap\u0131lan bir \u00e7ok \u00e7al\u0131\u015fmada, sigara i\u00e7en kad\u0131nlar\u0131n erkeklere g\u00f6re akci\u011fer kanserine daha yatk\u0131n oldu\u011fu g\u00f6sterilmi\u015ftir. Burada \u00f6strojen resept\u00f6rleri (ER) ve progesteron resept\u00f6rleri (PR) \u00fczerinden bir etki oldu\u011fu bunun da p53 geni ili\u015fkili bulundu\u011funu ifade bildiren \u00e7al\u0131\u015fmalar vard\u0131r (14,88). Bu \u00e7al\u0131\u015fmalar do\u011frultusunda, sigaran\u0131n akci\u011fer ve meme kanseri geli\u015fimini benzer mekanizmalar ile tetikleyebilece\u011fini s\u00f6ylemek yanl\u0131\u015f olmayacakt\u0131r (13).<br \/><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Alkol kullan\u0131m\u0131 meme kanseri riskini art\u0131rmaktad\u0131r. Kanser geli\u015fme olas\u0131l\u0131\u011f\u0131 t\u00fcketilen alkol miktar\u0131 ile do\u011fru orant\u0131l\u0131 olarak artmaktad\u0131r. Alkol\u00fcn meme kanseri geli\u015fimine etkisi, hipotalamusu etkileyerek l\u00fcteinizan hormon (LH) d\u00fczeyinde yapt\u0131\u011f\u0131 de\u011fi\u015fikliklere ba\u011flanmaktad\u0131r. Alkol t\u00fcketiminin hipotalamo-pit\u00fciter-gonadal sistem \u00fczerine etkisinin doza ba\u011f\u0131ml\u0131 olarak melatonin salg\u0131s\u0131n\u0131 ile de yak\u0131ndan ili\u015fkili oldu\u011fu g\u00f6zlenmi\u015ftir. Literat\u00fcrde, bunun en \u00f6nemli g\u00f6stergesi olarak alkol kullanan kad\u0131nlarda 24 saatlik idrarda at\u0131lan melatoninin metaboliti olan 6 s\u00fclfatoksimelatonin miktar\u0131 oldu\u011fu belirtilmektedir (90).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2dbc53e elementor-widget elementor-widget-heading\" data-id=\"2dbc53e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">1.C.Tiplendirme <\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ddc2b2 elementor-widget elementor-widget-heading\" data-id=\"7ddc2b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">C.1.Tiplendirmenin histolojik temeli  <\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d74915b elementor-widget elementor-widget-text-editor\" data-id=\"d74915b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Meme kanserinin bir kad\u0131n\u0131n hayat\u0131 boyunca ne zaman ve hangi etyolojik ajanla tetiklenece\u011fi hala tart\u0131\u015fma konusu olmaya devam etmektedir. Bununla beraber ge\u00e7 menar\u015f ve 24 ya\u015f\u0131ndan evvel do\u011fum yapm\u0131\u015f olmak meme kanseri riskini azaltmaktad\u0131r. Bununla beraber 19 ya\u015f\u0131ndan \u00f6nce iyonize radyasyona maruziyet ve nulliparite patogenezde rol oynamaktad\u0131r. Burada dikkati yo\u011funla\u015ft\u0131rmak gereken kritik ayr\u0131nt\u0131, menar\u015f ile ilk do\u011fum ya\u015f\u0131 aras\u0131nda ge\u00e7en s\u00fcredir. Meme kanserinin patogenezini bu ba\u011flamda d\u00fc\u015f\u00fcnmek yerinde olacakt\u0131r. Meme kanserinin orijin ald\u0131\u011f\u0131 h\u00fccreler \u201cterminal dukto lobuler unite\u201d=TDLU ad\u0131 verilen b\u00f6lgede bulunur.<br \/><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Yap\u0131lan otopsi \u00e7al\u0131\u015fmalara g\u00f6re, TDLU terminal duktuslar (TD) ve duktuler h\u00fccrelerden olu\u015fur. Bu kompleks Lobul 1 olarak tan\u0131mlanmaktad\u0131r. Lobul 1 nullipar populasyonda kantitatif olarak daha yo\u011fun bulunmaktad\u0131r. \u00a0Buradan atipik TDLU ve duktal karsinoma in situ (DKIS) ya da atipik lobuler h\u00fccreler ve sonra lobuler karsinoma in situ (LKIS) geli\u015fimi s\u00f6z konusu olacakt\u0131r. \u00d6zetle Lobul 2 LKIS geli\u015fiminden sorumlu histopatolojik yap\u0131 olmaktad\u0131r. Lobul 2 den geli\u015fen Lobul 3 sklerozan adenozis-adenofibroma-apokrin kistlerin geli\u015fimine temel te\u015fkil etmektedir. Lobul 3 en geli\u015fen Lobul 4 ise \u201clactating adenoma\u201d geli\u015fiminden sorumlu tutulmaktad\u0131r (\u015eekil 1). Genel populasyon \u00fczerinde yap\u0131lan \u00e7al\u0131\u015fmalarda Lobul 1 oran\u0131\u00a0 %22.5, Lobul 2 oran\u0131 %37.3, Lobul 3 oran\u0131 %38.4 bulunmu\u015ftur. Hi\u00e7 do\u011fum yapmam\u0131\u015f kad\u0131n populasyonda Lobul 1 %45.9, Lobul 2 oran\u0131\u00a0 %47.2 ve Lobul 3 oran\u0131 ise %6.9\u00a0 olarak saptanm\u0131\u015ft\u0131r. Do\u011fum yapm\u0131\u015f populasyon \u00fczerinde yap\u0131lan \u00e7al\u0131\u015fmalarda Lobul 1 %16.9, Lobul 2 %35 ve Lobul 3 ise %47.9 olarak bulunmu\u015ftur. BRCA 1 ta\u015f\u0131y\u0131c\u0131lar\u0131 ve genetik yatk\u0131nl\u0131\u011f\u0131 olan populasyondan elde edilen doku \u00f6rneklerinde Lobul 1 %47.9, Lobul 2 %39.9 ve Lobul 3 oran\u0131n\u0131n ise %9.9 oldu\u011fu g\u00f6zlenmi\u015ftir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>\u00d6te yandan, mammoplasti ve mastektomi spesimenlerinin histopatolojik olarak incelenmesiyle tan\u0131mlanan bu lobul tipleri i\u00e7inde Lobul 1 oran\u0131n\u0131n, yukar\u0131da tan\u0131mland\u0131\u011f\u0131 hali ile nullipar populasyonda ve invazif kanserli hasta \u00f6rneklerinde t\u00fcm\u00f6r d\u0131\u015f\u0131 dokuda daha y\u00fcksek oranda bulunmas\u0131 olduk\u00e7a dikkat \u00e7ekicidir (\u015eekil 2).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9d82a10 elementor-widget elementor-widget-heading\" data-id=\"9d82a10\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">C.1.A.\u0130n situ karsinoma<\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cdccc0e elementor-widget elementor-widget-heading\" data-id=\"cdccc0e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><p><b><span style=\"font-size:14.0pt;line-height:115%\">Duktal karsinoma in situ (DK\u0130S) <\/span><\/b><span style=\"font-family: Roboto, sans-serif;font-style: inherit;text-transform: inherit\"><\/span><\/p><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b1da1ba elementor-widget elementor-widget-text-editor\" data-id=\"b1da1ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><u>\u0130nsidans-mikroskopik \u00f6zellikler<\/u><\/p><p>Duktal karsinoma in situ, D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (WHO) taraf\u0131ndan \u201cepitelyal h\u00fccrelerin, memenin duktal-lob\u00fcler sistemi taraf\u0131ndan s\u0131n\u0131rland\u0131r\u0131lm\u0131\u015f belirsiz veya net sitolojik atipinin oldu\u011fu ama invazive bile\u015fenin olmad\u0131\u011f\u0131 neoplastik proliferasyonu\u201d olarak tan\u0131mlanmaktad\u0131r.DK\u0130S yeni tan\u0131 meme karsinomlar\u0131n\u0131n %20-25\u2019ini olu\u015fturmaktad\u0131r. Son 40 y\u0131lda insidans\u0131 y\u00fczbinde 1.87\u2019den y\u00fczbinde\u00a0 32.5\u2019a kadar y\u00fckselmi\u015ftir. Bu insidans\u0131n artmas\u0131nda mamografinin taramalarda daha etkin kullan\u0131lmas\u0131n\u0131n rol\u00fc a\u00e7\u0131kt\u0131r. \u00c7\u00fcnk\u00fc olgular\u0131n %80-85 kadar\u0131 mammografik incelemelerdeki kalsifikasyonlar ile bulunabilmektedir. DK\u0130S olgular\u0131n\u0131n %20-30 kadar\u0131\u00a0 mammografik doku yo\u011funlu\u011funda art\u0131\u015f ile saptanabilirken e\u015flik eden mammografik doku distorsiyonlar\u0131\u00a0 da g\u00f6r\u00fclebilmektedir. Meme ba\u015f\u0131 ak\u0131nt\u0131lar\u0131 ve Paget hastal\u0131\u011f\u0131na e\u015flik edebilmektedir. (bizim makaleler)<br \/><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Olgular\u0131n %98.8 kadar\u0131 unisentrik olup segmental yay\u0131l\u0131m g\u00f6sterir (holland). Multisentrik DK\u0130S varl\u0131\u011f\u0131nda ise lezyonlar en az iki farkl\u0131 kadranda bulunan odaklar \u015feklindedir. Son zamanlarda cerrahi uygulamalarda \u201cmulltisentrik\u201d veya \u201cmultifokal\u201d lezyon kavramlar\u0131n\u0131n bu ba\u011flamda dikkatli kullan\u0131lmas\u0131 gereken terimler olup konuya cerrahi tedavinin meme koruyucu cerrahi bahsinde de\u011finilecektir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Tan\u0131 a\u015famas\u0131nda genellikle en kesin ve sa\u011fl\u0131kl\u0131 yakla\u015f\u0131m, palpe edilemeyen lezyonlarda mammografik veya ultrasonografik i\u015faretleme ile eksizyonel biyopsi yap\u0131lmas\u0131d\u0131r. DK\u0130S tan\u0131s\u0131 \u00f6zellikle 2 mm nin alt\u0131ndaki ve en az 2 duktal yap\u0131n\u0131n tutuldu\u011fu \u201clow nuclear grade\u201d lezyonlarda, \u00f6rnekleme \u201ctru-cut\u201d biyopsi y\u00f6ntemi ile yap\u0131lm\u0131\u015f olsa bile hastan\u0131n zarar g\u00f6rmemesi a\u00e7\u0131s\u0131ndan a\u00e7\u0131k biyopsi y\u00f6ntemini gerekli k\u0131labilecektir. Eksizyon materyalinin radyolojik incelemesi ile lezyonun tamamen \u00e7\u0131kar\u0131ld\u0131\u011f\u0131 teyid edilmeldir. Pratikte eksize edilen materyalin cerrah taraf\u0131ndan patolog ile beraber orientasyonunun \u00e7ok dikkatli yap\u0131lmas\u0131 ve \u00f6rneklemelerin, \u00f6zellikle geni\u015f eksize edilen lezyonlarda eksizyon materyalini merkezindeki 3 cm lik bir alan\u0131 i\u00e7erecek \u015fekilde, materyalin\u00a0 uzun aks boyunca 0.3-0.4 mm kal\u0131nl\u0131kta kesitler al\u0131narak yap\u0131lmas\u0131 tan\u0131y\u0131 daha sa\u011fl\u0131kl\u0131 koydurabilir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Eksize edilen materyalde histopatolojik olarak DK\u0130S saptanmas\u0131 durumunda g\u00fcvenli <\/span><u style=\"font-style: inherit; text-transform: inherit;\">cerrahi s\u0131n\u0131r\u0131n<\/u><span style=\"font-style: inherit; text-transform: inherit;\"> iyi tan\u0131mlanmas\u0131, re-eksizyon ve rek\u00fcrrens olas\u0131l\u0131\u011f\u0131n\u0131n azalt\u0131lmas\u0131 y\u00f6n\u00fcnden \u00f6nem ta\u015f\u0131r. Bunun yan\u0131nda g\u00f6zden ka\u00e7abilecek bir mikroinvazive odak hasta i\u00e7in ya\u015famsal \u00f6nem ta\u015f\u0131r. Ayr\u0131ca adjuvan tedavilerin planlanmas\u0131 a\u00e7\u0131s\u0131ndan da y\u00f6nlendirici olacakt\u0131r.\u00a0 \u00a0 \u00a0<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Prognostik a\u00e7\u0131dan bak\u0131ld\u0131\u011f\u0131nda memenin DK\u0130S lezyonlar\u0131nda;<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>1.\u00a0<span style=\"color: #7a7a7a;\">H\u00fccresel dizilim ve yap\u0131sal \u00f6zellik<br \/><\/span><\/span><span style=\"color: #7a7a7a; font-style: inherit; text-transform: inherit;\">2. Nekroz varl\u0131\u011f\u0131<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><span style=\"color: #7a7a7a;\">3. N\u00fckleer grade<br \/><\/span><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><span style=\"color: #7a7a7a;\"><br \/><\/span>Cerrah i\u00e7in takip a\u015famas\u0131nda son derece yararl\u0131 bilgiler i\u00e7erir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">a.H\u00fccresel dizilim ve yap\u0131sal \u00f6zellik: Bu kavram g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda DK\u0130S lezyonlar\u0131,<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 -Kribriform<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 -Mikropapiller<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 -Papiller<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 -Solid<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 -\u201cClinging\/flat\u201d<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Olarak tiplendirilebilir (\u015eekil 21-5a). H\u00fccresel dizilim ve yap\u0131sal \u00f6zellik g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda DK\u0130S lezyonlar\u0131 %62 oran\u0131nda yukar\u0131daki tiplerin bir veya bir ka\u00e7\u0131n\u0131n bir arada oldu\u011fu kar\u0131\u015f\u0131k bir yap\u0131 g\u00f6sterir. Tek ba\u015f\u0131na solid tip ise %31 oran\u0131ndad\u0131r. Mikropapiller DK\u0130S lezyonlar\u0131 ise n\u00fckleer grade ve nekroz varl\u0131\u011f\u0131ndan ba\u011f\u0131ms\u0131z olarak %71 oran\u0131nda multisentrik (yani farkl\u0131 kadranlarda odak varl\u0131\u011f\u0131) olma e\u011filimindedir. Mikropapiller DK\u0130S lezyonu olan hastalar\u0131n \u201cintraduktal papillamatozis\u201d y\u00f6n\u00fcnden dikkatli ara\u015ft\u0131r\u0131lmas\u0131 akademik bir ilgi alan\u0131d\u0131r. Bu lezyonun, solitern intraduktal papillom lezyonundan farkl\u0131 olarak intraduktal papillomatozis zemininde geli\u015fmi\u015febilece\u011fi ihtimali tart\u0131\u015fma konusudur. \u00d6te yandan intraduktal papillomatozis prekanser\u00f6z kabul edilmesine ra\u011fmen solitern intraduktal papillom prekanser\u00f6z kabul edilmez ve retroareolar yerle\u015fimlidir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>b.Nekroz: Histopatolojik incelemede komedo ve non-komedo olarak ayr\u0131labilir. Komedo nekroz duktusun ortas\u0131nda karyorektik debris varl\u0131\u011f\u0131 ile karakterizedir ve y\u00fcksek n\u00fckleer grade g\u00f6stergesi olabilir. S\u0131kl\u0131kla kalsifikasyonun e\u015flik etmesi s\u00f6z konusudur.\u00a0 \u00a0<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>c.N\u00fckleer grade: N\u00fckleer grade temel al\u0131narak DK\u0130S lezyonlar\u0131 d\u00fc\u015f\u00fck, orta ve y\u00fcksek olmak \u00fczere \u00fc\u00e7 k\u0131sma ayr\u0131l\u0131r. H\u00fccre n\u00fckleusu, eritrositlerin 1.5-2 kat\u0131 kadar hafif b\u00fcy\u00fcme g\u00f6stermi\u015fse ve uniform karakter ta\u015f\u0131yorsa ve n\u00fckleer membran d\u00fczenli kont\u00fcre sahipse ise buna \u201cd\u00fc\u015f\u00fck n\u00fckleer grade\u201d denir. E\u011fer h\u00fccre n\u00fckleusu eritrositlerin 2.5 kat\u0131ndan daha fazla, yo\u011fun kromatin i\u00e7erikli ve d\u00fczensiz membrana sahip ve uniform yap\u0131y\u0131 kaybetmi\u015fse buna \u201cy\u00fcksek n\u00fckleer grade\u201d denir. Orta n\u00fckleer grade h\u00fccreler ise uniform yap\u0131n\u0131n yer yer korundu\u011fu bir mikroskopik g\u00f6r\u00fcn\u00fcm arz eder.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>\u201cY\u00fcksek n\u00fckleer grade\u201d li DK\u0130S olgular\u0131 genellikle h\u00fccresel dizilim ve yap\u0131sal \u00f6zellik olarak solid veya mikropapiller olup komedo nekroz i\u00e7erirler. Komedo nekroz odaklar\u0131n\u0131n kalsifikasyon i\u00e7ermesi mamografilerde pleomorfik punktat mikrokalsifikasyonlara neden olabilir. Periduktal stromadaki desmoplastik reaksiyon ise palpable kitleye neden olabilir. Meme ba\u015f\u0131n\u0131n Paget hastal\u0131\u011f\u0131 s\u0131kl\u0131\u011f\u0131 \u201cy\u00fcksek n\u00fckleer grade\u201d li bir DK\u0130S olgusunu vurgulayabilir. \u201cD\u00fc\u015f\u00fck n\u00fckleer grade\u201d li DK\u0130S olgular\u0131 ise solid\/kribriform bile\u015fenli olup solid bile\u015fen daha az belirgindir. Nekroz yo\u011fun olmay\u0131p kalsifikasyonlar \u00e7ok daha k\u00fc\u00e7\u00fck odaklar halindedir. Bu tip olgular palpable bir kitleden \u00e7ok, s\u0131kl\u0131kla g\u00f6r\u00fcnt\u00fcleme bulgusu \u015feklinde insidental olarak cerrah\u0131n kar\u015f\u0131s\u0131na \u00e7\u0131kar.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Burada DK\u0130S olgular\u0131n\u0131n az rastlanan iki morfolojik t\u00fcr\u00fc daha oldu\u011funu ak\u0131lda tutmak klinik deneyim y\u00f6n\u00fcnden \u00f6nem ta\u015f\u0131r. Bunlardan ilki apokrin morfolojili DK\u0130S, di\u011feri ise kistik hipersekretuar DK\u0130S\u2019dur.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Apokrin morfolojili DK\u0130S, h\u00fccresel dizilim ve yap\u0131sal \u00f6zellik bak\u0131m\u0131ndan solid, mikropapiller ve kribriform bile\u015fenleri i\u00e7erebilir. Ayr\u0131ca komedo nekrozlu olabilece\u011fi gibi \u201cy\u00fcksek n\u00fckleer grade\u201d li olabilir. Fakat histopatolojik incelemede lobuller ve sklerozan adenozis alanlar\u0131na do\u011fru ilerleyebilmesi benign bir lezyon olan apokrin adenozisin ay\u0131r\u0131c\u0131 tan\u0131s\u0131nda zorluk yaratabilir.<br \/><br \/><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-81a2c84 elementor-widget elementor-widget-text-editor\" data-id=\"81a2c84\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><u>DK\u0130S tan\u0131s\u0131, klinik \u00f6zellikler ve yakla\u015f\u0131m<br \/><\/u><span style=\"font-style: inherit; text-transform: inherit;\"><u><br \/><\/u>Kistik hipersekretuar DK\u0130S ise makroskopik ve mikroskopik kistik hastal\u0131k zemininde geli\u015febilir. Hem makroskopik hem de mikroskopik incelemelerde kistin i\u00e7eri\u011fi, visk\u00f6z ve homojen eozinofilik materyal ile doludur. Bu nedenle palpable ve yo\u011fun i\u00e7erikli kistlerde cerrahi yakla\u015f\u0131m \u00f6zen ve dikkat ister. \u00d6zellikle bilateral makroskopik kistik hastal\u0131kta perimenopozal ya\u015f grubunda takip baz\u0131 \u00f6nemli klinik bulgular\u0131 g\u00f6z \u00f6n\u00fcnde tutmay\u0131 gerektirir. Multiple, bilateral olan ve m\u00fckerrer ince i\u011fne aspirasyonlar\u0131na ra\u011fmen tekrarlayan bu gibi olgularda kist i\u00e7eri\u011fi hemorajik ise \u00f6zellikle g\u00f6r\u00fcnt\u00fcleme bulgular\u0131 da dikkate al\u0131narak davran\u0131lmal\u0131 ve cerrahi olarak biyopsi karar\u0131 geciktirilmemelidir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>B\u00fct\u00fcn bunlar\u0131n yan\u0131nda invazif kanserlerin adjuvan tedavi s\u00fcrecinde, hem kemoterapinin hem de radyoterapinin, memenin duktal epiteli \u00fczerinde DK\u0130S morfolojisini taklid edebilecek de\u011fi\u015fiklikler yapabilece\u011fi ak\u0131lda tutulmal\u0131, neoadjuvan tedavi sonras\u0131 invazif kanserlerde cerrahi giri\u015fim zamanlamas\u0131 ve cerrahi g\u00fcvenlik s\u0131n\u0131r\u0131n\u0131n tayini hem patolog hem cerrah taraf\u0131ndan \u00f6nemli bir sorun olarak kalmaya devam etmektedir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>G\u00fcn\u00fcm\u00fczde DK\u0130S tan\u0131 ve tedavisinde Silverstein ve ark.\u2019\u0131n\u0131n \u00f6nerdi\u011fi \u201cgrade\u201d ve \u201cnekroz\u201d temelli histopatolojik yakla\u015f\u0131m h\u00fccre dizilim ve yap\u0131sal \u00f6zelliklerin farkl\u0131l\u0131\u011f\u0131ndan kaynaklanabilecek sorunlar\u0131 en aza indirerek Van Nuys kriterlerinin daha rahat belirlenmesine olanak tan\u0131maktad\u0131r (30). Bu durumda s\u0131n\u0131flama \u015fu \u015fekilde olmaktad\u0131r;<br \/><br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">1. \u201cHigh grade\u201d<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">2. \u201cNon high grade\u201d komedonekroz ile beraber<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\">3. \u201cNon high grade\u201d komedonekroz yok<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Ancak burada h\u00fccre polarizasyonu da dikkate al\u0131nmal\u0131 diyen ara\u015ft\u0131rmac\u0131lar bulunmaktad\u0131r (31). Bu nedenle gittik\u00e7e artan bir \u015fekilde art\u0131k molek\u00fcler parametreler \u00fczerinde durulmaktad\u0131r.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>DK\u0130S olgular\u0131n\u0131n tarama ve tarama ve tan\u0131s\u0131 dikkat ve deneyim gerektiren bir konudur. Fizik muayenede s\u0131kl\u0131kla bir bulgu yoktur. Mammografide mikrokalsifikasyon bulgusu bazen magnifiye g\u00f6r\u00fcnt\u00fcler ile yakalanmaktad\u0131r. \u0130nce i\u011fne aspirasyon biyopsileri invazive karsinom ile ay\u0131r\u0131c\u0131 tan\u0131 sa\u011flamamaktad\u0131r. Kal\u0131n i\u011fne ile yap\u0131lan vakumlu kor biyopsiler (VKB) daha y\u00fcksek sensitivite ve spesiviteye sahip olsa da %18 e yak\u0131n oranda \u00f6rnekleme hatalar\u0131 bildirilmektedir (47). Asl\u0131nda bu bir bak\u0131ma VKB ile saptananan DK\u0130S olgular\u0131nda a\u00e7\u0131k biyopsiyi zorunlu k\u0131lmaktad\u0131r. Bu a\u00e7\u0131dan bak\u0131ld\u0131\u011f\u0131nda mammografik veya ultrasonografik i\u015faretleme ile lezyonun eksizyonel biyopsi ile \u00e7\u0131kar\u0131lmas\u0131 definitif tedaviyi de olanakl\u0131 k\u0131labilmektedir (49).<br \/><br \/><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fa4c124 elementor-widget elementor-widget-text-editor\" data-id=\"fa4c124\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><u>DK\u0130S\u00a0 tedavisi<br \/><\/u><span style=\"font-style: inherit; text-transform: inherit;\"><u><br \/><\/u>Lokal ve sistemik olarak ikiye ayr\u0131l\u0131r. Lokal tedavi, mastektomi, radyoterapi, eksizyon+radyoterapi se\u00e7eneklerini i\u00e7erir. Sistemik tedavi ise hormonoterapi ile s\u0131n\u0131rl\u0131d\u0131r. Rek\u00fcrrensin in situ olabilece\u011fi gibi invazif kansere evrilerek olabilece\u011fi ak\u0131lda tutulmal\u0131d\u0131r. Hastal\u0131\u011f\u0131n asl\u0131nda metastaz yapmas\u0131 s\u00f6zkonusu olmasa da %1-2 oran\u0131nda aksiller tutulum olabilece\u011fi ak\u0131lda tutulmal\u0131d\u0131r. Lokal rek\u00fcrrensin invazif kanser olarak olmas\u0131 ise sa\u011f-kal\u0131msal bir sorunu beraberinde getirir.\u00a0 \u00a0 \u00a0\u00a0<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>DK\u0130S lokal tedavisinde mastektomi se\u00e7ene\u011fi:<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Olgular\u0131n %98 inde tam bir sa\u011falt\u0131m sa\u011flamaktad\u0131r (59,67).\u00a0\u00a0 Literat\u00fcr verileri, bu y\u00fcksek ba\u015far\u0131 oran\u0131n\u0131n,\u00a0 olgular\u0131n klinik prezentasyonun, palpable kitle veya salt radyolojik g\u00f6r\u00fcnt\u00fc bulgusu olup olmamas\u0131ndan ba\u011f\u0131ms\u0131z oldu\u011funu g\u00f6stermektedir. Bu durum ayn\u0131 zamanda Silverstein kriterlerinden de farkl\u0131 de\u011ferlendirilmelidir. Mastektomi sonras\u0131 rek\u00fcrrens\u00a0 ya atlanm\u0131\u015f bir invazif kanser varl\u0131\u011f\u0131ndan ya da ameliyat yerinde \u00f6zellikle fleplerde cerrahi eksizyon materyeline girmemi\u015f bir insitu odaktan geli\u015fir. Bu nedenle cerrah ameliyat sonras\u0131 hasta takibini titizlikle yapmal\u0131d\u0131r.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>DK\u0130S lokal tedavisinde meme koruyucu cerrahi (MKC) se\u00e7ene\u011fi:<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Mastektomiye g\u00f6re olgular\u0131n lokal kontrol\u00fcnde MKC daha s\u0131k ba\u015fvurulan bir y\u00f6ntem olmaya devam etmektedir. \u0130nvazive meme kanserlerinde mastektomi ve MKC yi kar\u015f\u0131la\u015ft\u0131ran \u00e7ok say\u0131da prospektif randomize \u00e7al\u0131\u015fma olmas\u0131na ra\u011fmen DK\u0130S olgular\u0131nda mastektomi ve MKC yi kar\u015f\u0131la\u015ft\u0131ran \u00e7al\u0131\u015fmalar yetersizdir. \u00d6te yandan DK\u0130S lezyonlar\u0131n\u0131n invazive rek\u00fcrrenslerinin MKC ile tedavi edilmesinin sa\u011falt\u0131ma katk\u0131s\u0131 da belirsizli\u011fini korumaya devam etmektedir. Selektif \u00f6strojen resept\u00f6r mod\u00fclat\u00f6rlerinin aktif klinik kullan\u0131m\u0131ndan \u00f6nceki d\u00f6nemlerde bile MKC sonras\u0131 radyoterapi (RT) uygulamas\u0131 ile 15 y\u0131ll\u0131k takiplerde %98\u2019e varan sa\u011fkal\u0131m oranlar\u0131 bildirilmi\u015ftir (53). G\u00fcn\u00fcm\u00fczde ise MKC sonras\u0131 invazive rek\u00fcrrenslere etki eden risk fak\u00f6rleri hakk\u0131nda tart\u0131\u015fmalar devam etmektedir. Sadece MKC ve RT uygulamas\u0131 sonras\u0131, invazive rek\u00fcrrense etki eden en \u00f6nemli iki fakt\u00f6r\u00fcn ya\u015f ve yetersiz cerrahi g\u00fcvenlik s\u0131n\u0131r\u0131 oldu\u011fu konusunda genel bir kan\u0131 bulunmaktad\u0131r. Burada \u00f6nemli olan 1 mm boyundaki bir DK\u0130S olgusunda 2 mm kadar bir g\u00fcvenli s\u0131n\u0131r b\u0131rakman\u0131n rek\u00fcrrensin \u00f6nlenmesindeki rol\u00fcd\u00fcr. E\u011fer 2 mm den az bir cerrahi g\u00fcvenlik s\u0131n\u0131r\u0131 var ise takipte hasta premenopozal olsa bile MG incelemenin zorunlu olabilece\u011fi ak\u0131lda tutulmal\u0131d\u0131r. NSABP B-17 \u00e7al\u0131\u015fmas\u0131n\u0131n verilerine g\u00f6re lokal rek\u00fcrrens 49 ya\u015f \u00f6ncesi hastalarda %15, 50-60 ya\u015f aras\u0131nda %10 ve 60 ya\u015f sonras\u0131nda ise %9 olarak bildirilmektedir (50). Bu bulgular\u0131 destekleyen geni\u015f hasta gruplar\u0131n\u0131 i\u00e7eren NSABP B-24 ve EORTC \u00e7al\u0131\u015fmalar\u0131 da (51) g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6zellikle premenopozal ve repr\u00fcd\u00fcktif ya\u015f grubu hastalarda en uygun tedavi se\u00e7ene\u011finin MKC sonras\u0131 RT ve Tamoxifen uygulamas\u0131 oldu\u011fu sonucuna var\u0131labilir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>\u00d6te yandan \u201cgrade\u201d ve histolojik \u00f6zelliklerin lokal rek\u00fcrrens \u00fczerine etkisi \u00f6nemli bir tart\u0131\u015fma konusudur. Yap\u0131lan geni\u015f hasta gruplar\u0131n\u0131 i\u00e7eren \u00e7al\u0131\u015fmalarda y\u00fcksek \u201cgrade\u201d ve\/veya komedo nekroz varl\u0131\u011f\u0131nda MKC ve RT uygulamas\u0131 sonras\u0131, d\u00fc\u015f\u00fck \u201cgrade\u201d lezyonlara g\u00f6re daha y\u00fcksek lokal rek\u00fcrrens oranlar\u0131 saptanm\u0131\u015ft\u0131r. Y\u00fcksek grade ve komedo nekrozlu DK\u0130S olgular\u0131n\u0131n ayn\u0131 tedavi modaliteleri sonras\u0131 10 y\u0131ll\u0131k takiplerde daha k\u0131sa s\u00fcrede rek\u00fcrrens g\u00f6sterdikleri de saptanm\u0131\u015ft\u0131r (50,51).<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Bununla beraber solid\/komedo tipinde DK\u0130S olgular\u0131n\u0131n \u201cclinging\u201d ve micropapiller DK\u0130S olgular\u0131na g\u00f6re, MKC ve RT sonras\u0131 2.25 ile 2.39 kat daha fazla rek\u00fcrrens oran\u0131na sahip olduklar\u0131 ad\u0131 ge\u00e7en \u00e7al\u0131\u015fmalarda g\u00f6sterilmi\u015ftir. \u201cClinging carcinoma\u201d WHO taraf\u0131ndan g\u00fcn\u00fcm\u00fczde \u201cflat epithelial atipia\u201d olarak tan\u0131mlanmaktad\u0131r. Palpable kitle veya meme ba\u015f\u0131 ak\u0131nt\u0131s\u0131 ile ba\u015fvuran hastalardaki DK\u0130S olgular\u0131, klinik belirti vermeksizin sadece mammografik olarak saptanan DK\u0130S olgular\u0131na g\u00f6re daha y\u00fcksek rek\u00fcrrens oranlar\u0131na sahiptir.\u00a0 \u00a0<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>\u00a0DK\u0130S olgular\u0131nda radyoterapi (RT) se\u00e7ene\u011fi<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>DK\u0130S olgular\u0131nda MKC sonras\u0131 RT uygulamas\u0131n\u0131n rek\u00fcrrensleri azaltt\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. Bu konuyla ilgili olarak 4 prospektif randomize \u00e7al\u0131\u015fma bulunmaktad\u0131r. NSABP B-17 \u00e7al\u0131\u015fmas\u0131 randomize edilmi\u015f 818 DK\u0130S olgusu \u00fczerinde ger\u00e7ekle\u015ftirilmi\u015f olup sadece MKC ve MKC sonras\u0131 50 Gy total meme RT alan hastalar\u0131 kar\u015f\u0131la\u015ft\u0131rm\u0131\u015ft\u0131r. Bu \u00e7al\u0131\u015fma 12.y\u0131l\u0131n sonunda lokal rek\u00fcrrens oran\u0131 MKC sonras\u0131 RT ile sadece MKC yap\u0131lan hastalardaki %30.8 den %14.9 a d\u00fc\u015ft\u00fc\u011f\u00fc g\u00f6stermi\u015ftir. Ayr\u0131ca ayn\u0131 \u00e7al\u0131\u015fmada, MKC sonras\u0131 RT uygulamas\u0131 yap\u0131lan grupta sadece MKC uygulanan gruba g\u00f6re lokal invazive kanser insidans\u0131n\u0131n %16.4 ten %7.1\u2019e d\u00fc\u015ft\u00fc\u011f\u00fc de g\u00f6sterilmi\u015ftir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>1010 hasta \u00fczerinde ger\u00e7ekle\u015ftirilen EORTC 10853 \u00e7al\u0131\u015fmas\u0131nda 10 y\u0131ll\u0131k takip sonras\u0131nda lokal rek\u00fcrrens oran\u0131n\u0131n MKC sonras\u0131 RT ile sadece MKC yap\u0131lan hastalardaki %26\u2019dan %15\u2019e d\u00fc\u015ft\u00fc\u011f\u00fc g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Ayn\u0131 \u00e7al\u0131\u015fmada MKC sonras\u0131 RT uygulamas\u0131 yap\u0131lan grupta sadece MKC uygulanan gruba g\u00f6re invazive kanser insidans\u0131n\u0131n %13\u2019ten %8\u2019e d\u00fc\u015ft\u00fc\u011f\u00fc g\u00f6zlenmi\u015ftir. Bununla beraber, gerek 1701 hasta i\u00e7eren UK ANZ \u00e7al\u0131\u015fmas\u0131 ve gerek 1067 hasta i\u00e7eren SweDICS \u00e7al\u0131\u015fmalar\u0131 da MKC sonras\u0131 50 Gy total meme RT verilmesinin hem lokal rek\u00fcrrensi hem de invazive kanser insidans\u0131n\u0131 k\u00fcm\u00fclatif olarak anlaml\u0131 azaltt\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>\u00d6zellikle Silverstein taraf\u0131ndan Van Nuys kriterlerinden yola \u00e7\u0131karak irdelenen geni\u015f lokal eksizyon sonras\u0131 RT uygulanmayabilece\u011fi konusu hakk\u0131nda yap\u0131lan \u00e7al\u0131\u015fmalar da klinik uygulamada dikkat \u00e7ekicidir. Burada lezyonun \u201cgrade\u201di, hastan\u0131n ya\u015f\u0131, cerrahi g\u00fcvenlik s\u0131n\u0131r\u0131n\u0131n geni\u015fli\u011fi, lezyonun b\u00fcy\u00fckl\u00fc\u011f\u00fc \u00f6nem kazanmaktad\u0131r. Genellikle 2.5 cm ye kadar olan t\u00fcm\u00f6rlerde \u201cgrade\u201d d\u00fc\u015f\u00fck veya orta ise 3-12 mm aras\u0131 bir g\u00fcvenlik s\u0131n\u0131r\u0131 hedef al\u0131nmal\u0131d\u0131r. Ancak bu tip lezyonlarda 5 y\u0131ll\u0131k rek\u00fcrrens oran\u0131n\u0131n %6.1 olarak saptand\u0131\u011f\u0131 \u00e7al\u0131\u015fmalar vard\u0131r. Bu oran y\u00fcksek \u201cgrade\u201d lezyonlarda %15.3\u2019e varabilmektedir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>Bu nedenle genel ge\u00e7erli g\u00f6r\u00fc\u015f DK\u0130S olgular\u0131nda MKC sonras\u0131 total meme RT uygulanmas\u0131n\u0131n lokal rek\u00fcrrensleri azaltt\u0131\u011f\u0131 ve invazive kanser insidans\u0131n\u0131 da d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fc y\u00f6n\u00fcndedir.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>DK\u0130S tedavisinde aksiller yakla\u015f\u0131m veya sentinel lenf nod\u00fcl\u00fc (SLN) biyopsisi<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>DK\u0130S invazive bir \u00f6zellik g\u00f6stermedi\u011finden aksiller diseksiyon gerekli g\u00f6r\u00fclmez. Geni\u015f serilerde MKC sonras\u0131 RT ve hormonoterapi g\u00f6rs\u00fcn ya da g\u00f6rmesin, uzun d\u00f6nem takiplerde aksiller lenf nod\u00fcl\u00fc metastaz\u0131 oran\u0131 %0.1\u2019den az bulunmu\u015ftur.\u00a0 Bu durum SLN biyopsisinin de rutin uygulanmas\u0131n\u0131n mutlak gereklili\u011finin sorgulanmas\u0131na neden olur. Ancak se\u00e7ilmi\u015f baz\u0131 y\u00fcksek riskli hastalarda e\u015flik eden invazive kanser olas\u0131l\u0131\u011f\u0131 g\u00f6z \u00f6n\u00fcne al\u0131narak SLN uygulanabilir. \u00d6zellikle tru-cut biyopsi ile tan\u0131s\u0131 konulmu\u015f DK\u0130S olgular\u0131nda %5-18 oran\u0131nda invazive kanser olabilece\u011fi d\u00fc\u015f\u00fcn\u00fcld\u00fc\u011f\u00fcnde bu tip hastalarda SLN biyopsi yap\u0131lmas\u0131 uygundur. \u00d6te yandan DK\u0130S mastektomiyi zorunlu k\u0131l\u0131yorsa mastektomi \u00f6ncesi haz\u0131rl\u0131k yap\u0131larak SLN biyopsi uygulanabilir. Klinik bulgu ile ba\u015fvuran DK\u0130S olgular\u0131nda mikroinvazive veya invazive odak varl\u0131\u011f\u0131 olas\u0131l\u0131\u011f\u0131 mutlaka d\u00fc\u015f\u00fcn\u00fclmeli, bu tip hastalarda %3-20 oran\u0131nda aksilla metastaz\u0131 olabilece\u011fi \u00f6ng\u00f6r\u00fclerek SLN karar\u0131 al\u0131nmal\u0131d\u0131r.<br \/><\/span><span style=\"font-style: inherit; text-transform: inherit;\"><br \/>SLN biyopsi \u00f6rneklemesinde aksiller mikrometastazlar\u0131n varl\u0131\u011f\u0131n\u0131n prognostik de\u011feri tart\u0131\u015fmal\u0131 oldu\u011fundan imm\u00fcnhistokimyasal boyama \u00f6nerilmemektedir. SLN \u00f6rneklemesinde saptanan h\u00fccresel gruplar\u0131n \u00e7oklukla artifakt olmas\u0131 imm\u00fcnhistokimyasal incelemenin de\u011ferini de d\u00fc\u015f\u00fcrmektedir. Ayr\u0131ca baz\u0131 \u00e7al\u0131\u015fmalarda biyopsi sonras\u0131 meme epitelyum h\u00fccrelerinin deplasman\u0131 s\u00f6z konusu olabilece\u011finden yalanc\u0131 pozitiflik durumu olabilece\u011fi g\u00f6sterilmi\u015ftir (103).<br \/><br \/><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4217d83 elementor-widget elementor-widget-text-editor\" data-id=\"4217d83\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Abb. EMA, DDT, ER, PR, LH \u00a0\u00a0<\/p><p><strong>Turkiye Klinikleri J Gen Surg-Special Topics 2013;6(2):1-6<\/strong><\/p><p><strong>Figure 2.1 ler 5.1 al\u0131nt\u0131 yap.<\/strong><\/p><p><strong>30n<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>1.A.Meme kanseri insidans\u0131 Meme kanseri insidans\u0131, 1940 y\u0131l\u0131ndan bu yana A.B.D de yap\u0131lan istatistiksel verilere g\u00f6re her y\u0131l i\u00e7in %1 olarak verilmektedir.(1) Maalesef, son 50 y\u0131l i\u00e7inde tan\u0131 ve tedavi&hellip;<\/p>","protected":false},"author":1,"featured_media":584,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_theme","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-surgery"],"_links":{"self":[{"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/posts\/537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/comments?post=537"}],"version-history":[{"count":43,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/posts\/537\/revisions"}],"predecessor-version":[{"id":583,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/posts\/537\/revisions\/583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/media\/584"}],"wp:attachment":[{"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/media?parent=537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/categories?post=537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mahmutcanyagmurdur.com.tr\/en\/wp-json\/wp\/v2\/tags?post=537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}